Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Magnus Leth-Møller has a total of 62 co-authors. Here are the top co-authors by number of shared publications:

  • Eva Greibe

    Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus N, Denmark

    3 shared publications
  • Jens Fuglsang

    Department of Obstetrics and Gynecology, Aarhus University Hospital, Aarhus, Denmark

    3 shared publications
  • Per Glud Ovesen

    Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark

    3 shared publications
  • Susanne Hede

    Healthcare service for families, Aarhus Municipality, Grøndalsvej 2, 8260 Viby J, Denmark

    3 shared publications
  • Ulla Kampmann

    Dept. of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark; Steno Diabetes Center Aarhus, Aarhus University Hospital, Palle Juul-Jensens Boulevard 11, 8200 Aarhus N, Denmark

    3 shared publications
  • Adam Hulman

    Steno Diabetes Center Aarhus, Aarhus University Hospital, Palle Juul-Jensens Boulevard 11, 8200 Aarhus N, Denmark; Dept. of Public Health, Aarhus University, Bartholins Allé 2, 8000 Aarhus C, Denmark

    2 shared publications

Latest Publications

  • Open Access

    Breastfeeding and infant growth in relation to childhood overweight – a longitudinal cohort study

    by Magnus Leth-Møller, Ulla Kampmann, Susanne Hede, Per G Ovesen, Adam Hulman, Sine Knorr


  • Open Access

    The association of fetal growth rate and growth in first year of life with childhood overweight: a cohort study

    by Magnus Leth-Møller, Ulla Kampmann, Susanne Hede, Per G. Ovesen, Adam Hulman, Sine Knorr

    Background: There is an increasing focus on the first 1000 days from conception to two years of age as a period of importance for future weight. We aimed to describe the interaction between fetal and infant growth and their association with and ability to predict childhood overweight. Methods: We used routinely collected fetal growth data from Aarhus University Hospital and child growth data from Aarhus Municipality, 2008–2018. The outcome was overweight at age 5–9 years. The fetal growth rates at weeks 28 and 34 were extracted from individual trajectories using mixed models. We identified patterns of infant BMI Z-score growth using latent class analysis and estimated odds ratios of overweight at age 5–9 years dependent on fetal and infant growth. Predictive capabilities were assessed by comparing areas under the ROC-curves (AUCROC) of the prediction models. Results: In 6206 children, we identified three infancy growth patterns: average, accelerated, and decelerated growth. We found 1.09 (95% CI: 1.06–1.12) greater odds of being overweight for every 10 g/week increase in fetal growth rate at week 34. Compared with average growth, accelerated infant growth was associated with 1.52 (95% CI: 1.20–1.90) greater odds of overweight. Combining fetal and infant growth, children with average fetal growth and accelerated infant growth had 1.96 (95% CI: 1.41–2.73) greater odds of overweight. Fast fetal growth with decelerated infant growth was not associated with being overweight (OR: 0.79 (95% CI: 0.63–0.98)), showing that infant growth modified the association between fetal growth and overweight. When fetal growth was added to a prediction model containing known risk factors, the AUCROC remained unchanged but infant growth improved the predictive capability (AUCROC difference: 0.04 (95% CI: 0.03–0.06)). Conclusion: Fetal and infant growth were independently associated with overweight, but distinct combinations of fetal and infant growth showed marked differences in risk. Infant, but not fetal, growth improved a prediction model containing known confounders.


  • Open Access

    Effect of Gestational Diabetes on Fetal Growth Rate and Later Overweight in the Offspring

    by Magnus Leth-Møller, Adam Hulman, Ulla Kampmann, Susanne Hede, Per G Ovesen, Sine Knorr

    Context: Children of women with gestational diabetes (GDM) are often born with a higher birthweight and have an increased risk of overweight during childhood. High fetal growth rate is also associated with being overweight in childhood. Objective: To examine excessive fetal growth rate as a mediator between GDM and overweight in the offspring. Methods: This was a longitudinal cohort study, using routinely collected data on children born between 2008 and 2014 in Aarhus, Denmark. Fetal biometrics were extracted from the patient records at Aarhus University Hospital and childhood weight from the health records at Aarhus Municipality Healthcare Service. We calculated growth trajectories for fetuses affected by GDM and for unaffected fetuses using cubic mixed model regression. We extracted individual fetal growth rate and estimated the contributing effect of fetal growth rate on the risk of being overweight in the 5- to 9-year-old offspring. Results: We included 6794 mother-child pairs, 295 with GDM. Fetal growth was higher in women with GDM from week 25, and the offspring had an increased risk of being overweight (odds ratio, 2.02 [95% CI, 1.44-2.84]). When adjusting for fetal growth rate in week 28, the effect attenuated by 15%, and to 1.10 (95% CI, 0.76-1.60) when further adjusting for prepregnancy body mass index. Conclusion: Pregnancies affected by GDM had higher fetal growth rate and the offspring had a higher risk of being overweight at age 5 to 9 years. Fetal growth rate in early third trimester was a mediator of up to 15% of this association, but prepregnancy body mass index contributed strongly as well.


  • Hemoglobin A1c Trajectories During Pregnancy and Adverse Outcomes in Women With Type 2 Diabetes: A Danish National Population-Based Cohort Study

    by Anna S. Koefoed, Sine Knorr, Jens Fuglsang, Magnus Leth-Møller, Adam Hulman, Dorte M. Jensen, Lise Lotte T. Andersen, A. Emilie Rosbach, Peter Damm, Elisabeth R. Mathiesen, et al.

    OBJECTIVE: To identify and characterize groups of pregnant women with type 2 diabetes with distinct hemoglobin A1c (HbA1c) trajectories across gestation and to examine the association with adverse obstetric and perinatal outcomes. RESEARCH DESIGN AND METHODS: This was a retrospective Danish national cohort study including all singleton pregnancies in women with type 2 diabetes, giving birth to a liveborn infant, between 2004 and 2019. HbA1c trajectories were identified using latent class linear mixed-model analysis. Associations with adverse outcomes were examined with logistic regression models. RESULTS: A total of 1,129 pregnancies were included. Three HbA1c trajectory groups were identified and named according to the glycemic control in early pregnancy (good, 59%; moderate, 32%; and poor, 9%). According to the model, all groups attained an estimated HbA1c <6.5% (48 mmol/mol) during pregnancy, with no differences between groups in the 3rd trimester. Women with poor glycemic control in early pregnancy had lower odds of having an infant with large-for-gestational-age (LGA) birth weight (adjusted odds ratio [aOR] 0.57, 95% CI 0.40–0.83), and higher odds of having an infant with small-for-gestational age (SGA) birth weight (aOR 2.49, 95% CI 2.00–3.10) and congenital malformation (CM) (aOR 4.60 95% CI 3.39–6.26) compared with women with good glycemic control. There was no evidence of a difference in odds of preeclampsia, preterm birth, and caesarean section between groups. CONCLUSIONS: Women with poor glycemic control in early pregnancy have lower odds of having an infant with LGA birth weight, but higher odds of having an infant with SGA birth weight and CM.


  • Open Access

    Diabetes Technology in Pregnant Women with Type 1 Diabetes—Distribution and Effects on Glycemic Regulation and Perinatal Outcomes

    by Sara Yalda Ghaur, Pernille Bundgaard Grinderslev, Magnus Leth-Møller, Per Glud Ovesen, Jens Fuglsang, Sanne Fisker, H. David McIntyre, Ulla Kampmann

    Pregnancies complicated by type 1 diabetes (TID) are associated with an increased risk of obstetric and neonatal adverse outcomes. Optimal glycemic control prior to and through pregnancy is crucial to reduce complications. The use of diabetes technology is rapidly increasing. The aim of the study was to investigate the use and effects of diabetes technology in pregnant women with type 1 diabetes. A retrospective cohort study was conducted; 84 women were included in the analysis and were divided into subgroups according to their glucose monitoring method and insulin delivery method. HbA1c values declined during pregnancy in all subgroups with no significant difference between the subgroups. A difference was, however, found in birth weight z-scores. Women using a sensor and an insulin pump had larger babies compared to women without these treatment modalities. The results of the study indicate that diabetes technology, including insulin pumps and/or glucose sensors are not superior to self-monitoring blood glucose measurement and multiple daily injection insulin therapy, which is comforting in the light of the unequal access to health benefits.


  • Open Access

    Transplacental Transport of Artificial Sweeteners

    by Magnus Leth-Møller, Christina Søndergaard Duvald, Sofie Stampe, Eva Greibe, Elke Hoffmann-Lücke, Michael Pedersen, Per Glud Ovesen

    The prevalence of obesity is increasing, and the origins of obesity and metabolic dysfunction may be traced back to fetal life. Currently, overweight pregnant women are advised to substitute sugar-sweetened beverages with diet drinks containing artificial sweeteners. Recent evidence suggests that the consumption of artificial sweeteners during pregnancy increases the risk of obesity in the child, but the mechanism is unknown. We hypothesized the transportation of artificial sweeteners across the placenta into the fetal circulation and the amniotic fluid. We included 19 pregnant women who were given an oral dose of acesulfame, cyclamate, saccharin, and sucralose immediately before a planned caesarean section. Nine women were included as controls, and they refrained from an intake of artificial sweeteners. The maternal and fetal blood and amniotic fluid were collected during the caesarean section, and concentrations of artificial sweeteners were measured using mass spectrometry. We found a linear relationship between the fetal plasma concentrations of artificial sweeteners and the maternal plasma concentrations, with adjusted coefficients of 0.49 (95% CI: 0.28–0.70) for acesulfame, 0.72 (95% CI: 0.48–0.95) for cyclamate, 0.51 (95% CI: 0.38–0.67) for saccharin, and 0.44 (95% CI: 0.33–0.55) for sucralose. We found no linear relationship between amniotic fluid and fetal plasma concentrations, but there were positive ratios for all four sweeteners. In conclusion, the four sweeteners investigated all crossed the placenta and were present in the fetal circulation and amniotic fluid.


  • Open Access

    Artificial Sweeteners in Breast Milk: A Clinical Investigation with a Kinetic Perspective

    by Sofie Stampe, Magnus Leth-Møller, Eva Greibe, Elke Hoffmann-Lücke, Michael Pedersen, Per Ovesen

    Artificial sweeteners (ASs) are calorie-free chemical substances used instead of sugar to sweeten foods and drinks. Pregnant women with obesity or diabetes are often recommended to substitute sugary products with ASs to prevent an increase in body weight. However, some recent controversy surrounding ASs relates to concerns about the risk of obesity caused by a variety of metabolic changes, both in the mother and the offspring. This study addressed these concerns and investigated the biodistribution of ASs in plasma and breast milk of lactating women to clarify whether ASs can transfer from mother to offspring through breast milk. We recruited 49 lactating women who were provided with a beverage containing four different ASs (acesulfame-potassium, saccharin, cyclamate, and sucralose). Blood and breast milk samples were collected before and up to six hours after consumption. The women were categorized: BMI < 25 (n = 20), BMI > 27 (n = 21) and type 1 diabetes (n = 8). We found that all four ASs were present in maternal plasma and breast milk. The time-to-peak was 30–120 min in plasma and 240–300 min in breast milk. Area under the curve (AUC) ratios in breast milk were 88.9% for acesulfame-potassium, 38.9% for saccharin, and 1.9% for cyclamate. We observed no differences in ASs distributions between the groups.


  • Open Access

    Development and validation of an LC–MS/MS method for the quantification of artificial sweeteners in human matrices

    by Eva Greibe, Magnus Leth‐Møller, Sofie Stampe, Per Ovesen, Michael Pedersen, Elke Hoffmann‐Lücke

    Artificial sweeteners are widely used as substitutes for sugar. The sweeteners are generally considered safe, however their whereabouts during pregnancy and lactation and the effect on child development are poorly explored. There is a need for new tools to measure these substances during pregnancy and lactation. Here, we describe the development and validation of a sensitive liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of acesulfame, cyclamate, saccharin and sucralose in human plasma, umbilical cord blood, amniotic fluid and breast milk. The samples were prepared by protein precipitation and separated on a Luna Omega Polar C18 column (2.1 × 50 mm, 1.6 μm). Electrospray ionization in negative mode and multiple reaction monitoring were used to monitor the ion transitions. The validated concentration ranges were from 1 to 500 ng/ml (10–500 ng/ml for sucralose). Interassay precisions were all ≤15% and the accuracies were within ±15%. Stability, linearity, dilution integrity, carryover and recovery were also examined and satisfied the validation criteria. Finally, this analytical method was successfully applied on spiked samples of plasma, umbilical cord blood, amniotic fluid and breast milk, proving its suitability for use in clinical studies on artificial sweeteners, including during pregnancy and lactation.


  • Top Cited Papers

    Placental superoxide dismutase 3 mediates benefits of maternal exercise on offspring health

    by Joji Kusuyama, Ana Barbara Alves-Wagner, Royce H. Conlin, Nathan S. Makarewicz, Brent G. Albertson, Noah B. Prince, Shio Kobayashi, Chisayo Kozuka, Magnus Møller, Mette Bjerre, et al.


  • Maternal prepregnancy body mass index and physical activity during pregnancy assessed by accelerometer

    by Mette B. Andersen, Eva B. Ostenfeld, Jens Fuglsang, Magnus Møller, Merete Daugaard, Per G. Ovesen